Dossier assessment
Radium-223-dichloride - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Radium-223-dichloride - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
-
Dossier assessment
Radium-223-dichloride - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Press releases
Radium-223 dichloride in prostate cancer: major added benefit for certain patients
In comparison with BSC: Patients survive longer and get bone symptoms later / no evaluable data in comparison with docetaxel
Additional information
Federal Joint Committee (G-BA)
2014-06-19 A G-BA decision was published.
Project details
- Project no.
- A14-02
- Commission
- Commission awarded on 16.12.2013 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Radium-223 dichloride (mCRPC) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed